Amgen Plans to Slash Jobs and 4 Stocks Hitting 52-Week Highs

Amerigroup Corp. (NYSE:AGP): Over 36 states could either be unprepared or unwilling to begin the insurance marketplaces mandated by the Affordable Care Act, the Associated Press reports, which cited a PricewaterhouseCoopers report. If states do not set up the exchanges, the federal government is to either operate them alone or partner with the states to do so, the news service said. The shares closed at $91.56, up $0.18 or 0.2% on the day. They have traded in a 52-week range of $37.57 to $91.55.

Amgen Inc. (NASDAQ:AMGN) intends to cut “hundreds” of jobs in Switzerland, according to Bloomberg. The shares closed at $86.35, up $1.27 or 1.49% on the day. They have traded in a 52-week range of $52.85 to $85.34.

Are these stocks a buy or sell? Let us help you decide. Check out our Wall St. Cheat Sheet Stock Picker Newsletter now >>

Computer Task Group (NASDAQ:CTGX) lengthened its stock repurchase plan beneath Rule 10b5-1 of the SEC for the facilitation of the repurchase of its common stock. The company had nearly 550,000 shares available to be repurchased as of September 28 under its outstanding repurchase authorizations. The plan is to begin on October 4 and end the day after the company releases its 2012 Q3 financial results. The shares closed at $16.93, up $0.43 or 2.61% on the day. They have traded in a 52-week range of $9.68 to $16.66.

Google Inc. (NASDAQ:GOOG) Motorola unit has withdrawn one of its patent complaints against Apple (NASDAQ:AAPL) which was under consideration by the ITC, reports Foss Patents. Foss thinks that it’s possible that Google made the move due to progress in settlement talks, and the website believes that a more probable reason for the change is due to a deficiency in Google’s case. The shares closed at $756.99, down $4.79 or 0.63% on the day. They have traded in a 52-week range of $480.60 to $765.00.

Eli Lilly And Company (NYSE:LLY) along with Boehringer Ingelheim announced patient-reported health outcomes data from a Phase II study of their investigational novel basal insulin analogue, LY2605541, in patients who have been diagnosed with type 2 diabetes. The results of the study indicated that along with clinical results that reveal a statistically significant 48 percent baseline adjusted reduction in nocturnal hypoglycaemia versus with insulin glargine, and patients who were treated with LY2605541 reported a much lower amount of anxiety and fear regarding the experience of a hypoglycaemic event based upon the Adult Low Blood Sugar Survey, or ALBSS. The data is to be presented at the 48th European Association for the Study of Diabetes, or EASD, Annual Meeting in Berlin, Germany. Hypoglycaemia data was collected via a Phase II clinical study that compared LY2605541 with insulin glargine in patients diagnosed with type 2 diabetes, and along with the reduction in nocturnal hypoglycaemia in LY2605541-treated patients, results indicated that the treatments had similar overall rates of hypoglycaemia. The shares closed at $47.94, up $0.37 or 0.78% on the day. They have traded in a 52-week range of $35.46 to $47.76.

Don’t Miss: Are Airlines Making Their Comeback?